Form 4: electroCore Director Julie Ann Goldstein Reports Stock Option Grant

Director Julie Ann Goldstein reported the acquisition of stock options in electroCore, Inc. on September 3, 2024.

Summary

• Julie Ann Goldstein, a director of electroCore, Inc. (ECOR), reported a transaction on September 3, 2024.
• The transaction involved the acquisition of 19,845 stock options with an exercise price of $6.03.
• These options vest in 12 equal monthly installments from the grant date, with full vesting occurring earlier of the day before the next annual stockholder meeting or immediately prior to a change of control, contingent on continuous service.
• Following the reported transaction, Goldstein directly owns 19,845 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither inherently positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of 12 months is fairly standard, although some companies may offer more accelerated vesting schedules based on performance or other milestones.
• The exercise price of $6.03 would need to be compared to the current market price of electroCore's stock to determine the 'in-the-money' value of the options at the time of grant.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.

Key Dates